U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07474636) titled 'Efficacy and Safety Study of HS-10542 for IgA Nephropathy' on Feb. 26.
Brief Summary: This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.
Study Start Date: March 17
Study Type: INTERVENTIONAL
Condition:
IgAN
Immunoglobulin A Nephropathy (IgAN)
Glomerular Disease
Intervention:
DRUG: HS-10542 High Dose
Drug: HS-10542 High Dose, QD
DRUG: HS-10542 Low Dose
Drug: HS-10542 Low Dose, QD
DRUG: Placebo
Placebo, QD
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu Hansoh Pharmaceutica...